Overview
Rhodococcus equi is a facultative intracellular pathogen belonging to the Actinobacteria phylum. First isolated from foals in 1923, it exhibits unique virulence factors including a virulence-associated plasmid (VapA) and the ability to survive within macrophages. The bacterium demonstrates remarkable environmental adaptability, thriving in soil and manure where it can persist for extended periods. In veterinary medicine, R. equi is the causative agent of pyogranulomatous pneumonia in foals, while in humans it primarily affects immunocompromised individuals, particularly HIV/AIDS patients. Its distinctive red pigmentation results from carotenoid production, which may contribute to oxidative stress resistance.
Physical and Chemical Properties
As a Gram-positive bacterium, R. equi possesses a thick peptidoglycan cell wall containing mycolic acids, giving it partial acid-fast staining properties similar to Mycobacterium. The organism grows optimally at 30-37°C, forming smooth, mucoid colonies that develop salmon-pink to brick-red pigmentation within 48-72 hours on blood agar. The bacterium's cell wall contains unique glycopeptidolipids that contribute to environmental persistence. Its membrane composition includes branched-chain fatty acids (anteiso-C15:0 and anteiso-C17:0) that maintain fluidity under varying temperatures. R. equi produces extracellular enzymes such as cholesterol oxidase, which serves as both a virulence factor and an industrial enzyme.
Main Applications
In biomedical research, R. equi serves as a model organism for studying intracellular pathogen-host interactions and macrophage evasion mechanisms. Its cholesterol oxidase enzyme has applications in clinical diagnostics for cholesterol quantification and in industrial processes for steroid biotransformation. The bacterium shows promise in bioremediation due to its ability to degrade complex hydrocarbons, including petroleum contaminants and polycyclic aromatic hydrocarbons. Some strains are employed in biodesulfurization of fossil fuels. Recent studies explore its potential in nanoparticle synthesis and as a vector for vaccine delivery.
Safety and Storage
As a BSL-2 organism, R. equi requires containment measures including biological safety cabinets for culture work. Laboratory personnel should wear gloves, gowns, and respiratory protection when handling concentrated cultures. Immunocompromised individuals should avoid direct contact with the bacterium. For preservation, freeze-drying (lyophilization) in skim milk medium at -80°C provides long-term stability. Working cultures are typically maintained on brain-heart infusion agar at 4°C for short-term storage. All waste materials must be autoclaved before disposal, and work surfaces should be decontaminated with 70% ethanol or 10% bleach solutions.
B2B Procurement Guide
Research institutions should verify strain authenticity through whole-genome sequencing when purchasing from culture collections. Key specifications include virulence plasmid status (VapA+ or VapA-), antibiotic resistance profile, and source host information. Clinical isolates require additional documentation of patient consent and ethical approval. Industrial users seeking bioremediation strains should request hydrocarbon degradation efficiency data. For enzyme production, inquire about specific activity measurements of cholesterol oxidase or other target enzymes. Consider purchasing master cell banks for process consistency in manufacturing applications. Always confirm compliance with national regulations for pathogenic microorganism transport.